Compare AbbVie Inc (ABBV) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Gitlab Inc — how do they compare? AbbVie Inc trades at $248.42 (market cap $441.94B), while Gitlab Inc trades at $41.31 (market cap $7.11B). The key difference: AbbVie Inc is far larger — about 62.2× Gitlab Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals.
| ABBV | GTLB | |
|---|---|---|
Market Cap | $441.94B | $7.11B |
Sector | Health | Technology |
52-Week High | $263.58 | $51.04 |
52-Week Low | $197.38 | $19.42 |
Enterprise Value | $506.19B | $5.85B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
GitLab (GTLB) trades at $40.73, up 4.52% today, with a bullish technical signal from moving averages and a consensus analyst price target of $32.92. Recent earnings beats in Q3 2025 to Q1 2026 highlight strong execution, while revenue grew to $759.25 million in 2025. The stock's high P/E of 521.22 reflects growth expectations, but negative net income and cash flow pose challenges.
Outlook: Growth in DevSecOps and AI-driven software demand supports upside, but profitability risks and high valuation require caution. Key catalysts include continued revenue expansion and path to positive cash flow, while competition and execution missteps are primary risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
